Patents by Inventor Khalid Shah

Khalid Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134880
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: January 2, 2025
    Publication date: May 1, 2025
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 12227481
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: February 18, 2025
    Assignee: Exelixis, Inc.
    Inventor: Khalid Shah
  • Publication number: 20250051284
    Abstract: The present disclosure relates to tyrosine kinase inhibitors of Formula I and Compound 1, or pharmaceutically acceptable salts thereof. The present disclosure further relates to processes for the preparation of the tyrosine kinase inhibitors, Formula I and Compound 1, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 3, 2022
    Publication date: February 13, 2025
    Inventors: Khalid SHAH, Frenel DEMORIN, Sagar SHAKYA, Yong WANG, Wei XU
  • Publication number: 20250032611
    Abstract: Technology provided herein relates to methods of treating cancer comprising administering to a subject in need thereof a first stem cell (SC) modified to release an oncolytic virus and a second SC which is gene edited to inactivate a receptor for the oncolytic virus, thereby generating a stem cell resistant to the virus, wherein the second SC is also engineered to express an immunomodulatory polypeptide agent. Compositions comprising a first and second SC, and uses thereof, are also provided herein.
    Type: Application
    Filed: November 10, 2022
    Publication date: January 30, 2025
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Khalid SHAH
  • Publication number: 20250025510
    Abstract: This technology describes novel cell based combined therapeutic modalities that include a stem cell engineered to secrete a multispecific T cell engager (MiTE) polypeptide construct and an isolated population of T cells that are autologous to the subject.
    Type: Application
    Filed: December 1, 2022
    Publication date: January 23, 2025
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Khalid SHAH, Filippo ROSSIGNOLI
  • Publication number: 20250017916
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: September 27, 2024
    Publication date: January 16, 2025
    Inventors: Jo Ann Wilson, Khalid Shah
  • Patent number: 12128039
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: October 29, 2024
    Assignee: Exelixis, Inc.
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20240307367
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Application
    Filed: May 10, 2024
    Publication date: September 19, 2024
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Publication number: 20240300897
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Application
    Filed: May 7, 2024
    Publication date: September 12, 2024
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Patent number: 12017995
    Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Frenel DeMorin, Khalid Shah, Sagar Shakya, Peter Wong, Courtney S. Johnson, Melanie Janelle Bevill, Stephan D. Parent
  • Patent number: 12016882
    Abstract: This technology describes novel cell based combined therapeutic modalities that induces mechanism based tumor cell killing in a broad spectrum of sensitive and resistant tumors. These new agents are tumor specific and target a broad spectrum of solid tumors.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 25, 2024
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Khalid Shah
  • Patent number: 12016854
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: June 25, 2024
    Assignee: Exelixis, Inc.
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Publication number: 20240189298
    Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
    Type: Application
    Filed: February 8, 2024
    Publication date: June 13, 2024
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20240156804
    Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 16, 2024
    Inventors: Jo Ann Wilson, Khalid Shah
  • Publication number: 20240010621
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Application
    Filed: June 29, 2023
    Publication date: January 11, 2024
    Inventor: Khalid Shah
  • Publication number: 20230382867
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 30, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Publication number: 20230301978
    Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
    Type: Application
    Filed: October 28, 2022
    Publication date: September 28, 2023
    Inventors: Khalid Shah, Gisela Schwab, Steven Lacy
  • Patent number: 11760726
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Patent number: 11731941
    Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: August 22, 2023
    Inventor: Khalid Shah
  • Patent number: 11724986
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 15, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah